Discussion about the importance of clinical trial data disclosure in consideration of the current situation of research on PD-1/PD-L1 antibodies in China

LI Xin; LI Ting; SUN Fei-fei; TAO Ye; JIANG Xin; WANG Chen-jing; CAO Yu

doi:10.3969/j.issn.1003-3734.2023.06.002

Home>Articles>Discussion about the importance of clinical trial data disclosure in consideration of the current situation of research on PD-1/PD-L1 antibodies in China

DOI: 10.3969/j.issn.1003-3734.2023.06.002

Discussion about the importance of clinical trial data disclosure in consideration of the current situation of research on PD-1/PD-L1 antibodies in China

LI Xin

LI Ting

SUN Fei-fei

TAO Ye

JIANG Xin

WANG Chen-jing

CAO Yu

Machine-generated Keywords：

Publication Date：2023-03-31

Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)

Pages：7( 560-566 )

Chinese Journal of New Drugs

ISTICPKU

ISSN：1003-3734

Year, Vol.(Issue)：2023,(6)